Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

G Behre, A Behning, C Wickenhauser… - Bone marrow …, 2014 - nature.com
The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …
被引用次数：136 相关文章

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

N Jaekel, G Behre, A Behning… - Bone Marrow …, 2013 - europepmc.org
The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …

[引用][C] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

N JAEKEL, G BEHRE, A BEHNING… - Bone marrow …, 2014 - pascal-francis.inist.fr
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with
the JAK1 and JAK2 inhibitor ruxolitinib CNRS Inist Pascal-Francis CNRS Pascal and …

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

N Jaekel, G Behre, A Behning… - Bone marrow …, 2014 - pubmed.ncbi.nlm.nih.gov
The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

N Jaekel, G Behre, A Behning… - Bone Marrow …, 2014 - search.ebscohost.com
The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …

[引用][C] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

N Jaekel, G Behre, A Behning… - Bone Marrow …, 2013 - cir.nii.ac.jp
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the
JAK1 and JAK2 inhibitor ruxolitinib | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

N Jaekel, G Behre, A Behning… - Bone Marrow …, 2014 - go.gale.com
The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

N Jaekel, G Behre, A Behning… - Bone Marrow …, 2014 - search.ebscohost.com
The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing
symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic …

[引用][C] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

N Jaekel, G Behre, A Behning… - Bone Marrow …, 2014 - Nature Publishing Group